Mirdametinib Receives NICE Recommendation
04 September 2026
NICE (The National Institute for Health and Care Excellence) has reviewed the evidence submissions and external assessment report and has reached a conclusion to recommend Mirdametinib as an option to treat symptomatic, inoperable plexiform neurofibromas associated with Neurofibromatosis Type 1 in children and young people aged 2 to 17 years.
As part of the key stakeholders group, Nerve Tumours UK welcomes this recommendation as there will now be a treatment for under 3 years of age, but have raised questions and are still awaiting answers, as there is not a clear explanation post 17 years.